PRRT2 and cancer: The genetic variants identified affect many key cancer-related regulatory networks including the PI3K/AKT/MTOR, RAS/RAF/MEK/MAPK, JAK/STAT, PLC/PKC signalling pathways, DNA damage repair (DDR) pathways and cell cycle and immune checkpoints.